Cynapsus Therapeutics Inc Share Price

Stocks

Delayed Toronto S.E.			5-day change	1st Jan Change
- ^CAD	-.--%		+0.21%	-

06-03	HyProMag Ltd is 100% Owned by Maginito Ltd, Which is Owned on a 79.4%/20.6% Basis by Mkango Resources and CoTec	MT
06-03	HyProMag USA LLC is Owned 50:50 by CoTec and HyProMag Limited	MT

06-03	HyProMag Ltd is 100% Owned by Maginito Ltd, Which is Owned on a 79.4%/20.6% Basis by Mkango Resources and CoTec	MT
06-03	HyProMag USA LLC is Owned 50:50 by CoTec and HyProMag Limited	MT
06-03	CoTec JV, HyProMag USA, to Commence Preparatory Work for Project Execution Phase at Dallas-Fort Worth Texas Hub	MT
05-20	CoTec Releases Updated Mineral Resource and "Positive" PEA for Lac Jeannine Iron Tailings Project; Lost Near 10% on Tuesday	MT
11/03/24	Mkango and CoTec Brief: Mkango Subsidiary, Maginito, And CoTec Appointed Lead Engineers BBA And Pegasus To Complete Feasibility Study for HyProMag USA	MT
29/01/24	CoTec Holdings Outlines Key Targets For 2024	MT
03/01/24	Mkango Surges Near 12% As Forms HyProMag Joint Venture In US With CoTec	MT
10/10/23	Mkango Surges 11% As Says To Commence Feasibility Study For Proposed US Operation With CoTec	MT
10/10/23	Mkango, CoTec To Commence Feasibility Study For Proposed US Operation	MT
02/10/23	CoTec Completed Conversion of 2 Million Pounds Mkango Loan Note to Double Equity Position in Maginito to 20.6%	MT
14/09/23	Mkango Down Near 3% As Agrees To Form US Joint Venture With CoTec Holdings	MT
14/09/23	CoTec Holdings, Mkango To Form US Joint Venture	MT
30/06/23	Kings Chapel Increases Stake In CoTec Holdings	MT

05-06	COPPER INTELLIGENCE TO FORM AN EARLY-STAGE EXPLORATION JOINT VENTURE WITH COTEC TO TARGET PROCESSING HISTORICAL COPPER TAILINGS OPPORTUNITIES IN THE DEMOCRATIC REPUBLIC OF CONGO	PR
31/08/16	Cynapsus Therapeutics : Sunovion Pharmaceuticals to Acquire Cynapsus Therapeutics	PU
29/08/16	Cynapsus Therapeutics : Receives FDA Fast Track Designation for APL-130277 for the Treatment of OFF Episodes in Patients with Parkinson's Disease	GL
15/08/16	Cynapsus Therapeutics : Announces Positive Opinion from Data and Safety Monitoring Board on Phase 3 Parkinson's Disease Clinical Study Allowing for At-Home Titration	GL
12/08/16	Cynapsus Therapeutics : Announces Publication in the Journal Movement Disorders of Data for the Treatment of OFF Episodes in Patients with Parkinson's Disease	GL

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CYNAPSUS THERAPEUTICS INC	-.--%	+0.21%	-	-	0
WUXI APPTEC CO., LTD.	-1.90%	+2.85%	+62.82%	+104.13%	70.07B
ARGENX SE	-3.21%	-4.32%	+31.85%	+57.27%	52.87B
INSMED INCORPORATED	-2.05%	-5.61%	-3.18%	+449.71%	27.02B
WUXI BIOLOGICS (CAYMAN) INC.	-1.27%	-1.57%	+45.90%	+8.25%	23.61B
BIONTECH SE	+1.05%	-0.62%	-18.00%	-11.93%	23.38B
PHARMAESSENTIA CORPORATION	+3.81%	+20.97%	+266.37%	+531.28%	19.43B
GENMAB A/S	+0.10%	+1.40%	+35.36%	-19.94%	18.75B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-0.95%	-3.52%	+19.93%	+594.00%	15.85B
EXELIXIS, INC.	+1.24%	-5.23%	+33.75%	+137.66%	12.7B
Average	-0.32%	+1.95%	+52.76%	+205.60%	29.3B
Weighted average by Cap.	-1.09%	+0.55%	+50.23%	+164.99%